Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00410423 · ClinicalTrials.gov registry record · Phase 1
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT00410423 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 55 participants.
The verdict
NCT00410423, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
Based on what is known about it's mechanism of action, bortezomib is presumed to make other chemotherapy drugs work better. This study examines the use of bortezomib in combination with an already effective chemotherapy regimen that is used to treat leukemias that have relapsed or been refractory to treatment.
Interventions
- DRUG Bortezomib with mitoxantrone, etoposide and cytarabine
- DRUG Bortezomib 1.0mg/m^2
- DRUG Bortezomib 1.3mg/m^2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2006-01 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00410423
The ClinicalTrials.gov registry entry for NCT00410423 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bortezomib with mitoxantrone, etoposide and cytarabine is the first listed.
NCT00410423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00410423 about?
NCT00410423 is a clinical study titled "Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias". Based on what is known about it's mechanism of action, bortezomib is presumed to make other chemotherapy drugs work better. This study examines the use of bortezomib in combination with an already effective chemotherapy regimen that is used to treat leukemias that have relapsed or been refractory to...
What is the current status of trial NCT00410423?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2006-01. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00410423?
The interventions under investigation include: Bortezomib with mitoxantrone, etoposide and cytarabine (DRUG), Bortezomib 1.0mg/m^2 (DRUG), Bortezomib 1.3mg/m^2 (DRUG).
Who is sponsoring clinical trial NCT00410423?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.